Literature DB >> 32840724

Prediction of maternal pharmacokinetics using physiologically based pharmacokinetic models: assessing the impact of the longitudinal changes in the activity of CYP1A2, CYP2D6 and CYP3A4 enzymes during pregnancy.

Khaled Abduljalil1, Amita Pansari2, Masoud Jamei2.   

Abstract

Concerns over gestational effects on the disposition of drugs has highlighted the need for a better understanding of drug distribution and elimination during pregnancy. This study aimed at predicting maternal drug kinetics using a physiologically based pharmacokinetic (PBPK) modelling approach focusing on the observed gestational changes in three important Cytochrome P450 metabolizing enzymes, namely, CYP1A2, CYP2D6 and CYP3A4 at different gestational weeks (GWs). The Pregnancy PBPK model within the Simcyp Simulator V19 was used to predict the pharmacokinetics of sensitive probes to these enzymes; namely caffeine, theophylline, metoprolol, propranolol, paroxetine, midazolam, nifedipine and rilpivirine. PBPK model predictions were compared against clinical data collated from multiple studies for each compound to cover a wide spectrum of gestational ages. Pregnancy PBPK model predictions were within 2-fold error and indicated that CYP1A2 activity is approximately 0.70, 0.44 and 0.30 fold of the non-pregnant level at the end of the first, second and third trimesters, respectively. On the other hand, CYP2D6 activity increases by 1.36, 2.16 and 3.10 fold of the non-pregnant level at the end of the first, second and third trimesters, respectively. Likewise, CYP3A4 activity increases by 1.25, 1.75 and 2.32 fold of the non-pregnant level at the end of the first, second and third trimesters, respectively. The enzymes activity have been qualified throughout pregnancy. Quantified changes in drug dosing are most relevant during the third trimester, especially for drugs that are mainly eliminated by CYP1A2, CYP2D6 and CYP3A4 enzymes. The provided functions describing the continuous changes to the activity of these enzymes during pregnancy are important when modelling long term pharmacokinetic studies where longitudinal modelling or time-varying covariates are used.

Entities:  

Keywords:  CYP1A2; CYP2D6; CYP3A4; Inter-individual variability; PBPK; Pharmacokinetics; Pregnancy

Year:  2020        PMID: 32840724     DOI: 10.1007/s10928-020-09711-2

Source DB:  PubMed          Journal:  J Pharmacokinet Pharmacodyn        ISSN: 1567-567X            Impact factor:   2.745


  8 in total

Review 1.  The Impact of Pregnancy on Antihypertensive Drug Metabolism and Pharmacokinetics: Current Status and Future Directions.

Authors:  Ian R Mulrenin; Julian E Garcia; Muluneh M Fashe; Matthew Shane Loop; Melissa A Daubert; Rachel Peragallo Urrutia; Craig R Lee
Journal:  Expert Opin Drug Metab Toxicol       Date:  2021-11       Impact factor: 4.481

Review 2.  Predicting Human Fetal Drug Exposure Through Maternal-Fetal PBPK Modeling and In Vitro or Ex Vivo Studies.

Authors:  Ankit Balhara; Aditya R Kumar; Jashvant D Unadkat
Journal:  J Clin Pharmacol       Date:  2022-09       Impact factor: 2.860

3.  Application of a Physiologically Based Pharmacokinetic Model to Predict Cefazolin and Cefuroxime Disposition in Obese Pregnant Women Undergoing Caesarean Section.

Authors:  Hanadi H Alrammaal; Khaled Abduljalil; Victoria Hodgetts Morton; R Katie Morris; John F Marriott; Hsu P Chong; Hannah K Batchelor
Journal:  Pharmaceutics       Date:  2022-05-30       Impact factor: 6.525

4.  Non-clinical considerations for supporting accelerated inclusion of pregnant women in pre-licensure clinical trials with anti-HIV agents.

Authors:  Rick Greupink; Hedwig van Hove; Felix Mhlanga; Peter Theunissen; Angela Colbers
Journal:  J Int AIDS Soc       Date:  2022-07       Impact factor: 6.707

5.  Application of a Physiologically Based Pharmacokinetic Approach to Predict Theophylline Pharmacokinetics Using Virtual Non-Pregnant, Pregnant, Fetal, Breast-Feeding, and Neonatal Populations.

Authors:  Khaled Abduljalil; Iain Gardner; Masoud Jamei
Journal:  Front Pediatr       Date:  2022-05-12       Impact factor: 3.569

6.  Prediction of Maternal and Fetal Acyclovir, Emtricitabine, Lamivudine, and Metformin Concentrations during Pregnancy Using a Physiologically Based Pharmacokinetic Modeling Approach.

Authors:  Khaled Abduljalil; Amita Pansari; Jia Ning; Masoud Jamei
Journal:  Clin Pharmacokinet       Date:  2022-01-24       Impact factor: 6.447

7.  Prediction of Maternal and Fetal Doravirine Exposure by Integrating Physiologically Based Pharmacokinetic Modeling and Human Placenta Perfusion Experiments.

Authors:  R Greupink; A Colbers; V E Bukkems; H van Hove; D Roelofsen; J J M Freriksen; E W J van Ewijk-Beneken Kolmer; D M Burger; J van Drongelen; E M Svensson
Journal:  Clin Pharmacokinet       Date:  2022-05-17       Impact factor: 5.577

8.  Successful Prediction of Human Fetal Exposure to P-Glycoprotein Substrate Drugs Using the Proteomics-Informed Relative Expression Factor Approach and PBPK Modeling and Simulation.

Authors:  Olena Anoshchenko; Flavia Storelli; Jashvant D Unadkat
Journal:  Drug Metab Dispos       Date:  2021-08-23       Impact factor: 3.922

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.